Form 8-K - Current report:
SEC Accession No. 0000950170-25-026100
Filing Date
2025-02-25
Accepted
2025-02-25 08:15:09
Documents
13
Period of Report
2025-02-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20250225.htm   iXBRL 8-K 58880
2 EX-99.1 cadl-ex99_1.htm EX-99.1 41995
3 GRAPHIC img160460863_0.jpg GRAPHIC 33227
  Complete submission text file 0000950170-25-026100.txt   277098

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20250225.xsd EX-101.SCH 27880
15 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20250225_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 25659508
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)